A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Prior treatment

• Have a self-reported change (increase or decrease) in body weight \>5 kilogram (kg) within 3 months prior to screening

Other illness

• Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2
• Have acute or chronic hepatitis
• Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years

• Have a body mass index (BMI) of ≥30 kilogram/square meter (kg/m²) and ≤40 kg/m²
• Willing to learn how to self-inject study intervention (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study intervention; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study intervention)
• Male or female contraceptive use by participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.